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Hepatocytes represent an important target for gene therapy
and editing of single-gene disorders. In a-1 antitrypsin
(AAT) deficiency, one missense mutation results in impaired
secretion of AAT. In most patients, lung damage occurs due
to a lack of AAT-mediated protection of lung elastin from
neutrophil elastase. In some patients, accumulation of mis-
folded PiZ mutant AAT protein triggers hepatocyte injury,
leading to inflammation and cirrhosis. We hypothesized that
correcting the Z mutant defect in hepatocytes would confer a
selective advantage for repopulation of hepatocytes within an
intact liver. A human PiZ allele was crossed onto an im-
mune-deficient (NSG) strain to create a recipient strain
(NSG-PiZ) for human hepatocyte xenotransplantation. Results
indicate that NSG-PiZ recipients support heightened engraft-
ment of normal human primary hepatocytes as compared
with NSG recipients. This model can therefore be used to test
hepatocyte cell therapies for AATD, but more broadly it serves
as a simple, highly reproducible liver xenograft model. Finally,
a promoterless adeno-associated virus (AAV) vector, express-
ing a wild-type AAT and a synthetic miRNA to silence the
endogenous allele, was integrated into the albumin locus.
This gene-editing approach leads to a selective advantage of
edited hepatocytes, by silencing the mutant protein and aug-
menting normal AAT production, and improvement of the
liver pathology.
INTRODUCTION
a-1 antitrypsin deficiency (AATD) is a common genetic disorder that
can lead to both liver and lung disease and currently affects an esti-
mated 3.4 million patients worldwide.1 AAT is encoded by SERPINA1
and is primarily secreted by hepatocytes, making it themost abundant
serum antiprotease. One of the most common disease variants in
AATD is a mutation resulting in a glutamate to lysine (Glu342Lys)
substitution known as the PiZ allele or Z-AAT.2 In contrast to the
normal PiM allele (M-AAT) the Z-AAT protein is prone to poly-
merization and consequently is either directed for proteolysis or
aggregates in the endoplasmic reticulum of hepatocytes.3 With up
to 85% of the AAT protein being retained as polymers or degraded
in the liver, it sets the stage for both the loss-of-function (lung) and
gain-of-function (liver) diseases observed in AATD patients.
Normally, AAT diffuses into all organs, but its main site of action is
the lower respiratory tract, where it protects the alveoli and the sur-
rounding connective tissue matrix from destruction by neutrophil
elastase. In this context, AATD patients develop panacinar emphy-
sema owing to years of a protease/antiprotease imbalance leading to
alveolar wall degradation and decreases in airway tethering as a
consequence of the loss of interstitial elastin.4 The Z-AAT aggrega-
tion and polymerization causes liver disease by a toxic gain-of-func-
tion mechanism due to accumulation of misfolded protein in the
hepatocytes whereby 10%–20% of PiZ homozygote patients suffer
from clinical liver disease ranging from fulminant liver failure and
cirrhosis to hepatocellular carcinoma.5–7 Development of these disor-
ders is thought to be a consequence of the intracellular accumulation
of Z-AAT polymers in hepatocytes leading to hepatocellular death by
apoptosis or other death mechanisms.
Insight into the pathobiology of the liver disease has been derived
from the PiZ mouse, which is a transgenic C57BL/6 mouse expressing
the human Z-AAT gene at high levels. In this model, polymer accu-
mulation is heterogeneous throughout the liver, and cells with lower
Z-AAT protein burdens proliferate to maintain liver mass, leading to
cycles of cell death and regeneration that end with the activation of
hepatic stellate cells and eventually hepatic fibrosis.8 Consequently,
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cells with higher Z-AAT protein burden have decreased mitotic
index.9
Currently, the treatment of AATD liver disease can only be addressed
by liver transplantation, and due to the associated morbidity, it is an
option for patients with significant cirrhosis, hepatocellular carci-
noma, and liver failure. In contrast, studies have shown a slower pro-
gression of the lung disease with weekly intravenous augmentation
therapy of purified pooled human plasma AAT.10,11 However, this
long-life therapy engenders considerable costs and lifestyle adjust-
ments; thus, AATD has been a target for gene-augmentation therapy.
Strategies for recombinant adeno-associated virus (AAV)-mediated
gene augmentation for the lung, and simultaneous gene augmenta-
tion with mutant gene reduction for both lung and liver disease
have been described.12–17 However, to our knowledge there are
currently no pre-clinical studies taking advantage of the competitive
disadvantage of Z-AAT-burdened hepatocytes compared to wild-
type murine hepatocytes that were previously documented in the
PiZ mouse.9
We therefore hypothesized that the cell death and regeneration cycle
in Z-AAT-burdened livers will allow normal donor human hepato-
cytes or genetically corrected murine hepatocytes to progressively
outcompete host hepatocytes expressing the mutant form of AAT.
This concept has important clinical implications for cell transplant
therapy, but it will also be highly relevant from the perspective of
genome editing. Specifically, determining if the genetic correction
of hepatocytes in AATD patients can lead to cells with increased
engraftment is crucial for this therapeutic approach. Here, we report
that the generation of the NOD-scid-gamma-PiZ transgenic mice
expressing mutant Z-AAT on the severe immune deficient NSG back-
ground allows for the repopulation of the liver by normal donor hu-
man hepatocytes as well as by murine hepatocytes corrected by
genome editing. The data supports the use of hepatocyte-transplant
and genome-editing approaches to treat emphysema and liver disease
in patients with AATD. Furthermore, this is a novel, potent, and tech-
nically simple approach to generate xeno-repopulation of the liver
with normal donor human hepatocytes or with induced pluripotent
stem cell-derived hepatic cells, and it may prove a useful tool for
the liver regeneration field.
RESULTS
Wild-Type Mouse Hepatocytes Have an Increased Engraftment
as Compared to PiZ Mouse Hepatocytes in the NSG-PiZ Mouse
It has been reported that Z-AAT globule-containing murine hepato-
cytes have an increased incidence of apoptosis and that this leads to
a proliferative disadvantage of these cells when compared to murine
hepatocytes with lower or no Z-AAT globule loads.8,9 In order to
confirm this hypothesis and determine whether normal donor hu-
man hepatocytes could regenerate a PiZ liver, we used the PiZ
mouse that expresses the human Z-AAT gene to create two new
strains. First, the PiZ mouse was backcrossed onto the NOD-scid
IL2rgnull (NSG) background.18 The severely immunocompromised
NSG-PiZ strain allows these mice to host human as well as alloge-
neic mouse hepatocytes without rejection. Second, we generated
the hepatocyte donor mice by crossing the transgenic C57BL/6-
Tg(CAG-EGFP)1Osb mouse strain with either a wild-type C57BL/
6 or a C57BL/6-PiZ transgenic mouse. These crosses generated
C57BL/6-Tg(CAG-EGFP)1Osb-PiZ F1 litters hemizygous for GFP
with (PiZ-GFP) or without (wild-type, WT-GFP) the PiZ mutant
human a-1 antitrypsin (AAT) gene (Figure 1A). As shown in Fig-
ure 1B, hepatocytes isolated from the PiZ-GFP mice expressed
both the human Z-AAT and GFP genes whereas the WT-GFP
donors only expressed GFP. Hepatocytes from these mice were
then used to engraft male NSG-PiZ mice by intrasplenic injection
of 1  106 PiZ-GFP or WT-GFP donor hepatocytes. Eight weeks
post-injection, livers from recipient NSG-PiZ mice were examined
for donor repopulation by digital droplet PCR (ddPCR) as well as
by immunohistology. The quantitative ddPCR data confirms that
that the level of donor hepatocyte repopulation in the NSG-PiZ
mouse is dependent on whether the donor hepatocytes express
the Z-AAT or not. The results in Figure 1C show that on average
40% of the hepatocytes of the NSG-PiZ livers were GFP positive
when mice were engrafted with wild-type GFP-expressing normal
hepatocytes as compared to only 5% when the donor hepatocytes
were expressing GFP and Z-AAT (PiZ-GFP). These results were
confirmed by immunohistochemical (IHC) and immunofluorescent
(Figures 1D–1G) staining of host livers where WT-GFP hepatocytes
engrafted at a significantly higher proportion as compared to the
PiZ-GFP hepatocytes. GFP IHC staining and positive pixel count
threshold analysis of the images revealed repopulation varied by
lobes between 32% and 48% (Table S1), but overall the positive pixel
count analysis for histology sections supports the ddPCR results.
This data confirms the hypothesis that wild-type murine hepato-
cytes have an increased regenerative capacity as compared to
Z-AAT containing hepatocytes and moreover that the Z-AAT-
burdened host liver is undergoing sufficient turnover to provide
wild-type donor hepatocytes with the ability to repopulate it at sig-
nificant levels.
Normal Human Hepatocytes Readily Repopulate NSG-PiZ
Mouse Livers
Given the increased fitness of normal mouse hepatocytes in NSG-PiZ
mice, we next sought to determine if this mouse strain could sustain a
human hepatocyte xenograft. To test this, NSG-PiZ and NSG control
mice were injected intrasplenically with 1 106 mature human hepa-
tocytes. Human albumin levels were monitored prospectively in
mouse sera samples as a surrogate for human liver repopulation.
Serum human albumin levels in Figure 2A confirm that liver chime-
rism is possible in these mice and that the level of human hepatocyte
repopulation achieved in NSG-PiZ mouse livers expressing the
Z-AAT is dramatically increased over that achieved in NSG mouse
livers. This again confirms the role for the Z-AAT burden in creating
a niche whereby wild-type hepatocytes are able to expand preferen-
tially. Given that the human hepatocytes also benefited from an
increased engraftment in the NSG-PiZ mice, we hypothesized that
increasing hepatocyte turnover may lead to increased repopulation.
To test this, we repeated the same experiments with an added partial
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Figure 1. Wild-Type Mouse Hepatocytes Have an Increased Engraftment as Compared to PiZ Mouse Hepatocytes in the NSG-PiZ Mouse
(A) Experimental outline, GFP-expressing hepatocytes from PiZ-GFP or wild-type (WT)-GFP donor mice were isolated and engrafted into male NSG-PiZ mice by intrasplenic
injection of 1 106 cells per mouse. The recipient mice were euthanized 8 weeks post-engraftment, and liver tissue was used for analysis. (B) Human Z-AAT and GFP gene
expression were determined by qRT-PCR in donor mice (mean ± SEM, n = 3). Statistical significance of the difference between donor cell types was determined by a two-
tailed, unpaired t test. ****Statistically significant difference; NS, not significant. (C) The percentage of GFP+ cells per diploid genomewas determined by ddPCR performed on
genomic DNA fromNSG-PiZmouse liver engrafted with PiZ-GFP orWT-GFP hepatocytes (mean ± SEM; controls, n = 2; PiZ-GFP, n = 3;WT-GFP, n = 4). Genomic DNA from
WT-GFP donor liver was used as a positive control. Presence of GFP+ cells is shown by (D and F) immunohistochemistry for all animals and (E and G) immunofluorescence for
one representative animal in NSG-PiZ mice engrafted with (D and E) PiZ-GFP hepatocytes and (F and G) WT-GFP hepatocytes.
www.moleculartherapy.org
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hepatectomy at the time of the intrasplenic injections. Given that in
mice the original liver mass is regenerated in about 7 days after a
70% partial hepatectomy,19 we hypothesized that during this prolifer-
ative phase wemay get increased repopulation. As shown in Figure 2B,
partial hepatectomy leads to a 5- to 10-fold increase in circulating
Figure 2. Normal Human Hepatocytes Readily
Repopulate NSG-PiZ Mouse Livers
Male NSG-PiZ and NSG mice were engrafted with
1  106 mature human hepatocytes, and serum was
collected biweekly post-engraftment for 10 weeks for
(A) quantification of human albumin levels by ELISA after
either intrasplenic engraftment alone (IE) or intrasplenic
engraftment with partial hepatectomy (PHx); data are
represented as mean ± SEM. **Statistically significant
differences between groups (two-way ANOVA). Liver tis-
sue was harvested at 10 weeks post-PHx and stained for
human albumin (B and C); one representative animal
is shown.
serum human albumin levels. Interestingly, in
the NSG mice, hepatectomy caused a decrease
in repopulation. This is likely due to the advan-
tage of wild-type-proliferating mouse hepato-
cytes over human hepatocytes in the context
of a mouse liver. IHC staining for human albu-
min in the NSG-PiZ mouse livers (Figure 2C)
confirmed that human hepatocytes are also
able to repopulate a significant portion of the
NSG-PiZ livers.
Z-AAT Burden in NSG-PIZ Mice Decreases
with Age, and Hepatocyte Repopulation
Correlates with Z-AAT Levels
It has been established that in PiZ transgenic
mice Z-AAT globule-containing hepatocytes
have a higher incidence of apoptosis and that
these cells tend to get outcompeted by hepato-
cytes with lower Z-AAT globule loads.8 This
phenomenon is likely the underlying basis for
the competitively advantaged repopulation of
wild-type murine or human hepatocytes in
NSG-PiZ mice. To more clearly define the con-
sequences of this normal hepatocyte turnover in
the absence of donor hepatocytes, we investi-
gated whether this natural turnover in NSG-
PiZ mice would also lead to a decrease in the
Z-AAT globule load over time. A prospective
analysis of serum Z-AAT levels in these mice
shows a clear and strong inverse correlation
(r2 = 0.80, p % 0.003, two-tailed) between the
age of the mice and the Z-AAT serum levels
(Figure 3A). As NSG-PiZ mice age, the serum
Z-AAT levels decrease, which is also reflected
histologically by the decrease in the globule-
containing status of the hepatocytes between 6 and 14 weeks of age.
This is clearly visualized by both a diastase-resistant periodic acid-
Schiff (PASD; Figures 3B and 3C) and human AAT staining of
livers at different ages (Figures 3D and 3E), consistently with
previous reports.20,21 This data suggests that in the absence of
Molecular Therapy
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engrafted wild-type hepatocytes, the liver in NSG-PiZ mice still exerts
enough selective pressure to favor survival and expansion of hepato-
cytes that produce and accumulate less Z-AAT. Interestingly, as the
mice age there are some hepatocytes that continue to accumulate
Z-AAT globules, and it appears that even though they are scarcer,
their globules tend to be larger (Figure 3C). As the Z-AAT burden de-
creases with the age of the mice, we would expect that the proliferative
advantage of the normal human engrafted hepatocytes would also be
diminished. To confirm if this was the case, we performed a retrospec-
tive analysis comparing the average human albumin level of a given
mouse to the Z-AAT serum level at the time of engraftment. Our
analysis revealed a moderate yet highly significant positive correlation
(r2 = 0.46, p% 0.0003) between Z-AAT serum levels and the levels of
human liver chimerism as determined by average human albumin
serum levels (Figure 3F).
Optimization of the Human Liver Xenograft Model
To investigate alternatives to the partial hepatectomy for increased hu-
man hepatocyte repopulation, we tested two approaches that have been
previously used in the liver xenograft field, namely monocrotaline
(MCT) and a mouse-specific anti-Fas antigen (CD95) antibody.
MCT is a pyrrolizidine plant alkaloid with known endothelial toxicity
in the lung, liver, and kidney and has been shown to increase cell repo-
pulation in the liver.22 The anti-CD95 antibody recognizes mouse Fas
and leads to cytolytic activity of cells expressing mouse Fas by inducing
apoptosis of mouse hepatocytes and other cells.23 We explored various
protocols employing these two liver injury models to create a “two hit”
protocol that can be easily and reproducibly performed without the
need for the partial hepatectomy. Repopulation was significantly
increased with both of these interventions and achieved levels compa-
rable or higher than with the partial hepatectomy (Figure 4A). We
administered either a single or two doses MCT (50 mg/kg) prior to
engraftment, with the highest levels achieved when mice were given
two MCT doses (Figure 4A). The kinetics of repopulation following a
single intraperitoneal injection of the anti-CD95 antibody at the time
of hepatocyte delivery was just as efficient as the partial hepatectomy
asdeterminedby the serumhuman albumin levels (Figure 4A). Staining
of the MCT- and CD95-treated mouse livers for human albumin
confirmed the repopulation of the human hepatocytes (Figure 4B).
Furthermore, a quantitative flow-cytometry analysis using an anti-
HLA antibody confirms that at least 25% of all hepatocytes in the
MCT-treatedmice are of human origin (Figure 4C). Human specificity
of the anti-HLA antibody was demonstrated by absence of staining of
strictly murine hepatocytes (Figure S1). The FDA-accepted therapeutic
serum threshold for protein augmentation of human AAT is currently
set at 11 mM, equivalent to 572 mg/mL. The results from the xenograft
experiments indicate for the first time that this threshold can be
achieved with a simple hepatocyte cell therapy approach. Quantifica-
tion of total humanAAT levels after human hepatocyte transplantation
in theNSG-PiZmice shows that it is possible to achieve this therapeutic
threshold and that it may be of clinically relevant interest when com-
bined with a partial hepatectomy (Figure 4D).
Figure 3. Z-AAT Burden in NSG-PiZ Mice Decreases with Age and Hepatocyte Repopulation Correlates with Z-AAT Levels
(A) Correlation between the age of NSG-PiZ mice and their serum Z-AAT levels. Serum was collected and Z-AAT levels were quantified by ELISA. Data are plotted as
mean ± SEM; n per group is as follows: 50 days, n = 10; 60 days, n = 9; 72 days, n = 27; 85 days, n = 12; 95 days, n = 17; 110 days, n = 7; 115 days, n = 3; 185 days, n = 5.
(B–E) Liver tissue from NSG-PiZ mice was stained for PASD (B and C) or human AAT (D and E) at 6 weeks of age (B and D) or 14 weeks of age (C and E); results are presented
for one representative animal. (F) Correlation between serum Z-AAT levels of the NSG-PiZ hosts at the time of engraftment and subsequent level of repopulation indicated by
serum human albumin 7 weeks post-engraftment. Serum was collected at engraftment and 7 weeks post-engraftment, and Z-AAT and human albumin levels (respectively)
were quantified by ELISA for 30 animals.
www.moleculartherapy.org
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Selective Expansion of Genome-Edited Hepatocytes
Adults andP1B6-PiZmicewere injected systemicallywith either saline
or AAV-GeneRide-DualFunctionAAT. GeneRide-DualFunctionAAT
is a promoterless cassette containing a 2A-peptide sequence followed
by a de-targeted, c-Myc-tagged humanAAT sequence, and an artificial
miRNA targeting Z-AAT.14 The cassette is flanked by two homology
arms (1.1–1.3 kb) that are complementary to the C57BL/6 Alb locus
and allow homologous recombination (HR). Following HR, Alb and
AAT will be co-transcribed as a single Alb-AAT mRNA—which will
be referred to here as “fused transcript”—and will lead to the produc-
tion of two proteins through ribosomal skipping (Figure 5A). To
measure the expression imparted by the genome-edited alleles, we
quantified by ddPCR the relative abundance of the fused mRNA tran-
script as compared to the normal albumin transcript in a subset ofmice
at 4, 6, and 8 months post-injection. The fused transcript is only
detected in the treated animals (Figure 5B). In adult-treated mice, at
4 months the ratio was 0.2%, while at 6 months it was increased to
3%; in P1-treated mice, at 6 months the ratio of 5.6%, and at
8 months it was increased to 7.2% (Figure 5B; one-way ANOVA,
p value% 0.0029), supporting expansion of the genome-edited hepa-
tocytes as function of time. These results were further confirmed by
measuring the c-Myc-tagged AAT in serum (M-AAT-c-Myc). Mice
were bled prior to injection and biweekly thereafter, which allowed
for monitoring of M-AAT-c-Myc serum levels by ELISA. The levels
ofM-AAT-c-Myc increase on average 10-fold over timewhen between
2 and 6 months in adult-treated mice, and such increase over time is
also observed in P1-treatedmice (Figure 5C). This difference in expres-
sionover time is statistically significant (two-wayANOVA,p<0.0001),
Figure 4. Optimization of the Human Liver Xenograft Model
(A) Repopulation rate was assessed after various challenges. The challenges compared were as follows: intrasplenic engraftment alone (IE, white circles), intrasplenic
injection with partial hepatectomy (PHx, red circles), a single intraperitoneal dose of 50 mg/kg monocrotaline (MCT) at 7 days pre-engraftment (1 MCT, blue crosses), a
double intraperitoneal dose of 50 mg/kg MCT at 14 and 7 days pre-engraftment (2 MCT, green triangles), and a dose of 1 mg CD95 intravenously (i.v.) at the time of
engraftment (CD95, gray squares). Serum was collected biweekly post-engraftment, and human albumin levels were quantified as a measure of repopulation. Data are
plotted as mean ± SEM. **Statistically significant differences between groups. (B) Liver tissue was harvested at 10 weeks post-engraftment from MCT-treated mice and
stained for human albumin; one representative animal is shown. (C) Hepatocytes of human origin were quantified by flow cytometry. Hepatocytes were gated as CD324+
cells, and human hepatocytes are defined as cells expressing the human HLA-ABCmarker within the CD324+ subset. One representative animal is shown. Percentages are
indicated in the histogram and dot plot. (D) Serum human AAT levels were quantified by ELISA in various treatment groups at 10 weeks post-engraftment. Data are plotted as
mean ± SEM. The dotted line denotes the therapeutic threshold at 572 mg/mL. ****Statistically significant difference between groups (two-way unpaired t test).
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Figure 5. Selective Expansion of Genome-Edited Hepatocytes
Adults or P1 PiZ mice were injected systemically with (A) recombinant AAV8 vector packaged with a promoterless, dual-function cassette containing an artificial miRNA that
targets human AAT and amiRNA-detargeted human AAT sequence with a c-Myc tag. The cassette is flanked by 1.1–1.3 kb homology arms to the albumin locus. Transgene
expression was evaluated by several methods. (B) Albumin-a-1 antitrypsin-fused transcript/murine albumin transcript ratio by ddPCR. **Statistically significant differences
over time (two-way ANOVA). (C) M-AAT-c-Myc serum levels by ELISA, normalized to the average of the age-matched control group. ****Statistically significant differences
both over time and between groups (two-way ANOVA). (D) c-Myc immunohistochemistry, quantified by threshold analysis with (E) representative animals shown for each
group (scale bar, 2 mm). (D) ****Statistically significant differences over time (two-way ANOVA). For all graphs, data are represented as mean ± SEM.
www.moleculartherapy.org
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further supporting expansion of the genome-edited hepatocytes as a
function of time. P1-treated animals present at all time points higher
M-AAT-c-Myc levels than age-matched adult-treated animals (Fig-
ure 5C). This difference between adult-treated and P1-treated is statis-
tically significant (two-way ANOVA, p value < 0.0001). This was
further confirmed in a subset of livers stained for c-Myc at 4, 6, and
8 months post-injection where the number of positive cells was
quantified (Figure 5D). The staining shows clusters of hepatocytes
throughout the entire liver (Figure 5E), and the size of the clusters
increases between early and late time points for both the adult-treated
and the P1-treated animals. This qualitative observation is supported
by a quantitative threshold analysis (Figure 5D), which estimates the
percentage of c-Myc positive pixel counts at 1.6% at 4 months and
2.6% at 6 months for the adult-treated mice and 11% at 6 months
and 18.8% at 8 months for the P1-treated animals. At 6 months of
age, the P1-treated animals present levels approximately 4-fold
higher than adult-treated animals. The differences observed were
statistically significant both between treatment groups (two-way
ANOVA, p value < 0.0001) and over time (two-way ANOVA,
p value < 0.0001).
Genome Editing Improves Liver Phenotype
The Z-AAT liver pathology is caused by polymerization of the Z-AAT
protein and accumulation of those polymers in globules. Clinically
the patients present with liver fibrosis, which may lead to cirrhosis
and hepatocellular carcinoma. Levels of serum Z-AATwere evaluated
by ELISA, and the percentage of Z-AAT silencing increases over time
(Figure 6A) and is statistically significant starting at 6 months in
adult-treated mice (two-tailed unpaired t test, p% 0.0002) and start-
ing at 4 months in P1-treated mice (two-tailed unpaired t test,
p % 0.0001). Consistent with the M-AAT-c-Myc data, silencing is
higher in the P1-treated animals than in the adult-treated animals
(two-way ANOVA, p % 0.0012). Interestingly, the magnitude of
Z-AAT silencing was unexpected given that it far exceeds the amount
of genome-edited hepatocytes. This finding has important implica-
tions and suggests that not all hepatocytes produce equal amounts
of Z-AAT, and perhaps, as suggested by our data, the highest degree
of proliferative advantage for the GeneRide (and thus Z-AAT
silencing) may be in those hepatocytes that continue to produce
and retain high amounts of Z-AAT. Alternatively, this could point
to the inverted terminal repeat (ITR)-driven expression of the anti-
AAT miRNA in unedited hepatocytes. Finally, the liver phenotype
was further characterized in P1-treated mice, at 6 months and
8 months post-treatment. A periodic acid-Schiff-diastase (PAS-D)
staining was performed on liver sections from those mice, in order
to assess the amount of Z-AAT globules that appear as magenta
spheres. As quantified in Figure 6B, the percentage of PAS-D+ cells
is significantly reduced by more than 100-fold at both 6 and 8 months
post-treatment (two-way ANOVA, p% 0.0001). A Picro Sirius Red
(PSR) staining was performed on liver sections from the male ani-
mals, in order to assess the amount of collagen fibers, which will
appear in red, as a measure of liver fibrosis. Quantification of PSR+
cells showed a reduction of over 40% at 8 months post-treatment
(Figure 6C, two-tailed unpaired t test, non-significant). Representa-
tive images are shown in Figures 6D and 6E for the PAS-D staining
and in Figures 6G and 6H for the PSR staining.
Taken all together, the data supports the hypothesis that HR
occurred in cells throughout the liver, that the genome-edited hepa-
tocytes then selectively expanded, and that this expansion results in
an increase of serumM-AAT with a concomitant decrease of Z-AAT
over time. This results in a marked improvement of the liver
pathology.
DISCUSSION
The current report demonstrates an in vivo survival advantage of
hepatocytes in which WT-AAT is expressed, as compared with those
expressing the common human missense mutant AAT, Z-AAT, in
line with a previous study in PiZ mice demonstrating that cell therapy
could partially improve the liver phenotype.24 Similarly, here we show
for the first time that gene-edited PIZ hepatocytes can also be cor-
rected to lower the Z-AAT burden and provide competitive survival
advantage to those hepatocytes, thereby normalizing serum AAT
levels and improving the toxicity in the liver imparted by the mis-
folded Z-AAT. Disorders in which corrected cells possess a compet-
itive survival advantage have been viewed as optimal candidates for
gene and cell therapy. In cases such as severe combined immune defi-
ciency (SCID) due to adenosine deaminase (ADA) deficiency, the sur-
vival advantage of corrected cells appears to contribute to the robust
clinical efficacy observed despite modest initial transduction effi-
ciency in early trials.25 A survival advantage in genetically corrected
hepatocytes has been demonstrated in the case of hereditary tyrosine-
mia type 1 due to fumarylacetoacetate hydrolase (FAH)-deficiency.26
The latter could present an opportunity for cell or gene therapy or
genome editing of this disease,27 if safety and efficacy prove to provide
an advantage over small-molecule therapy with 2-(2-nitro-4-trifluor-
omethylbenzoyl)-1,3-cyclohexanedione (NTBC). In the case of AAT
deficiency, no therapy currently exists to correct or prevent liver dis-
ease, and attempts to use intramuscular gene augmentation to secrete
WT-AAT and treat lung disease have been hampered by suboptimal
serum levels at the doses of vector used to date.15 Additionally, trans-
plantation of WT-AAT hepatocytes in an AAT-deficient patient with
end-stage liver disease previously resulted in an increase in AAT
serum levels from 12–19 mg/dL to 290 mg/dL.28
The competitive advantage for repopulation of non-PiZ-expressing
hepatocytes in the NSG-PiZ recipient also presents numerous oppor-
tunities to use this system as an experimental tool in both xenograft
and isograft settings. The Fah-deficient mouse strain has frequently
been used for a similar purpose. The NSG-PiZ mouse may represent
an alternative human hepatocyte repopulation model in which the
uncorrected animals breed and survive easily without maintenance
drug therapy. The human xenograft version of this system may be
used as an in vivo model to identify optimal vectors for transduction
of human hepatocytes, which often differ from mouse hepatocytes in
their tropism for specific AAV capsid variants.29 Similarly, human he-
patocyte xenografts are a useful tool for in vivo directed evolution
studies.30
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This study validates the NSG-PiZ mouse model as a platform to test
human hepatocyte cell-based therapy for liver disease and genome
editing for AATD. Besides disease-specific applications, the NSG-
PiZ mouse model offers an in vivo tool to evaluate the liver repopu-
lation ability of any cells with hepatocytic potential, including human
induced pluripotent stem cell-derived hepatic cells. Overall, this study
provides an important additional liver disease mouse model to the
liver regeneration field, which is needed to investigate ways to treat
human liver disease.
Future prospects for liver-directed cell and gene therapy of AAT defi-
ciency include innovations for in vivo or ex vivo genome editing with
nucleotide-directed endonucleases, such as CRISPR/Cas9 and Cpf1.
Many of the questions to be addressed regarding both safety and effi-
cacy depend on targeting human, as opposed to murine, hepatocytes.
For instance, studies of off-target effects of genome editing are only
valid in the context of the human genome. Likewise, the potential
for vector carcinogenesis due to recombinant AAV (rAAV) integration
cannot be readily extrapolated between species. This is particularly true
for liver-directed rAAV therapy, in which vector-related hepatocellular
carcinoma has been tracked to the Rian locus in murine cells. Because
of the dissimilarity in sequence between the murine and human loci,
the model presented here could potentially be of value in addressing
these and other related questions in future studies.
Figure 6. Genome Editing Improves Liver Phenotype
Z-AAT serum levels are decreased, as shown in (A) by ELISA, normalized to the average of the age-matched control group and presented as percentage of silencing.
*Statistically significant differences between treated and control groups at a given time point (unpaired t test); **statistically significant differences between treatment groups
(two-way ANOVA). Liver phenotype was further analyzed at 6 and 8 months post-treatment in the P1-injected group, by (B) PASD immunohistochemistry at 6 and 8months,
quantified by threshold analysis. ****Statistically significant differences between groups (two-way ANOVA). (C) Picro Sirius immunohistochemistry at 8 months, quantified by
threshold analysis; (D and E) representative animals for the PASD staining (D, control; E, treated); (F and G) representative animals for the PSR staining (F, control; G, treated).
For all graphs, data are represented as mean ± SEM.
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MATERIALS AND METHODS
Animals
NOD.Cg-PrkdcscidIl2rgtm1wjl/SzJ (NSG) and NSG-Tg(SERPINA1*
E342K)#Slcw/Sz (NSG-PiZ) mice were obtained from the research
colonies of Leonard D. Shultz at The Jackson Laboratory. FVB.Cg-Tg
(SERPINA1E342K*)#Slcw mice carrying the PiZ allele of the serpin
peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin),
member 1 (Homo sapiens) transgene were kindly provided by David
Perlmutter (University of Pittsburgh School of Medicine). This trans-
genic model possesses the Z variant (PiZ) allele of the human AAT
(SERPINA1*) transgene, allowing for human Z-AAT expression.
The PiZ allele31 was backcrossed five generations by a marker-assisted
speed congenic approach to the NSG strain background. NSG-
Tg(SERPINA1*E342K)#Slcw/Sz was abbreviated as NSG-PiZ mice.
The PiZ transgenic hemizygous mice were intercrossed to fix the
PiZ allele to homozygosity. NSG-PiZ homozygotes were raised in a
specific pathogen-free (SPF) barrier mouse room at The Jackson Lab-
oratory andmaintained by intercrossing homozygous breeders. NSG-
PiZ homozygotes were shipped to UMMS for hepatocyte engraft-
ment. The mice used for engraftment experiments were maintained
on sulfamethoxazole/trimethoprim in drinking water on alternate
weeks as previously described.32 Mice were housed with 12 hr light/
dark cycles on Bed-o’cob 1/4” bedding (Andersons), and fed a stan-
dard laboratory diet. Mice were not fasted before any of the proced-
ures. All procedures were carried out during the light cycle.
The B6-PiZ mice used for the genome-editing experiments have a
high transgene copy number (>10).
Animal Procedures
All animal procedures were performed according to the guidelines
indicated for rodent surgery on the Institutional Animal Care and
Use Committee webpage and by the Institutional Animal Care and
Use Committee of the University of Massachusetts Medical School.
Aseptic techniques and sterile instruments were used during all pro-
cedures. All recipient animals were males, age 6–10 weeks, and they
were anesthetized by isoflurane inhalation in a closed ventilation
chamber.
Intrasplenic Injection
An incision was made on mouse left paralumbar fossa in order
to expose the spleen. One million primary human hepatocytes
(Bioreclamation IVT) suspended in 50 mL of Hanks Balanced Saline
solution were injected into the inferior pole of the spleen, using a 25G
needle connected to a 1/3 mL syringe. The exposed spleen was re-
turned to the abdominal cavity, and the incision was closed with an
absorbable suture (4-0 Vicryl). Vet Bond was applied topically to
seal the skin incision.
Partial Hepatectomy
Amedian-line incision was made to expose the liver. The median lobe
of the liver and the left lateral lobe were securely tied off with 4-0 silk
Blake braided suture and excised. Two-thirds of the total liver was
removed by partial hepatectomy. The remaining liver was gently re-
turned to the abdominal cavity. Finally, the opposing sections of
the abdominal wall were aligned at the ventral midline, and an
absorbable suture (4-0 Vicryl) was applied to close the incision.
The skin incision was sealed with the topical application of Vet Bond.
Vector Injection for Genome Editing
For the treatment of adult mice, males between 5 and 9 weeks of age
received an intravenous injection of 1E12 gc of vector in 200 mL total
volume. For the treatment of P1 mice, both males and females were
injected intraperitoneally with 2E11 gc of vector. Animals were bled
biweekly via sub-mandibular puncture as per our protocol, and serum
was stored at80C until time of analysis. At endpoint, animals were
euthanized by CO2 asphyxiation followed by cervical dislocation as
per our protocol. Liver tissue was harvested, consistent sections
were fixed for histology, and the remaining tissue was snap-frozen
for downstream molecular analysis.
Liver Perfusion/Primary Hepatocyte Isolation
Mice were euthanized and an abdominal incision was made to expose
the abdominal cavity, and the viscera were arranged in order to
expose the inferior vena cava. A catheter needle was used to puncture
the inferior vena cava and inserted1 cm into the inferior vena cava.
Suture silks were applied to secure the catheter. Pump tubing was
attached to the end of the catheter. The portal vein was sliced to allow
outflow. The diaphragm was opened, and the inferior vena cava was
clamped off above the liver. To perfuse the liver, liver perfusion me-
dium (Life Technologies) was first pumped through the circulatory
system for 50 mL, followed by liver digest medium (Life Technolo-
gies) for 50 mL. The liver was removed and immersed in ice-cold he-
patocyte wash medium (HWM, Life Technologies) allowing for the
hepatocytes to diffuse into solution. The cell suspension was drawn
up and pipetted through 70 mm mesh and was centrifuged at 50 g
for 3min at 4C. After spinning down the cells, 10 mL of HWM
and 10 mL 90% Percoll (GE Healthcare) in phosphate-buffered saline
(PBS; Ca2+, Mg2+ free) were added to the solution to remove non-
viable cells. The hepatocyte solution was washed three times with
30 mL of HWM.
ELISA
The mouse sera were collected biweekly pre- and post-engraftment
and tested for total AAT, Z-AAT, c-Myc, and human albumin by
ELISA. For all assays, high binding 96-well plates (Immulon4, Dyna-
tech Laboratories) were coated with the relevant capture antibody in
100 mL Voller’s buffer overnight at 4C. Unless otherwise indicated,
all subsequent incubations were done at room temperature for 1 hr,
and plates were washed in between steps with PBS 0.05% Tween 20.
Human AAT ELISA
Blocking was done with 1%milk. Capture antibody is human-specific
goat anti-AAT (1:500, Cat#55111, MP Biomedicals); detection anti-
body is goat anti-hAAT (horseradish peroxidase [HRP]; 1:5,000,
Cat#ab191350, Abcam). Standard is AAT, (Cat# 16-16-011609,
Athens Research and Technology).
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Z-AAT ELISA
Blocking was done with 1% milk. Capture antibody is a custom
antibody (available through http://www.umassmed.edu/muellerlab/
contact/reagent-request); detection antibody is described above.
c-Myc ELISA
All incubations were done at 37C. Blocking was done with 5% BSA.
Capture antibody is (1:1,000, Cat# ab19234, Abcam).
Human Albumin ELISA
Human albumin levels were evaluated post-engraftment by using the
human Albumin ELISA quantitation set (Bethyl Labs) as described by
the manufacturer. For all assays, after incubation with the HRP-con-
jugated antibody, 3,3’,5,5’-tetramethylbenzidine (TMB) peroxidase
substrate (KPL) was applied, and the reactions were stopped by add-
ing 2 N H2SO4 (Fisher Scientific) after 15–30 min. Plates were read at
450 nm on a VersaMax microplate reader (Molecular Devices).
Immunohistochemistry
Mouse liver was serially sectioned 4 mm.
Human Albumin Staining
Sections were de-paraffinized and treated by Citra (Biogenex) at 98C
for 30 min. Background Sniper (Biocare Medical) was applied to
reduce non-specific background staining. Sections were incubated
with rabbit anti-human albumin (1:4,000, Cat#ab2604, Abcam) for
1 hr. Stain was visualized using Mach2 Goat  Rabbit HRP polymer
(Biocare Medical), the 3,3’-diaminobenzidine (DAB) chromagen
(Biocare Medical) and Churukian-Allison-Tacha (CAT) hematoxylin
counterstain (Biocare Medical).
Human AAT Staining
Slides were de-paraffinized with xylene and re-hydrated through
decreasing concentrations of ethanol to water, including an interme-
diary step to quench endogenous peroxidase activity (3% hydrogen
peroxide in methanol). Slides were transferred to 1 Tris-buffered
saline (TBS). For enzyme-induced antigen retrieval, sections were
heated for 5 min at 37C, while submerged in Digest-all Trypsin
(Invitrogen). Slides were subsequently rinsed in 1 TBS and incu-
bated with a universal protein blocker Sniper (Biocare Medical), for
15 min at room temperature (RT). Slides were rinsed in 1 TBS
and incubated for 60 min with a primary rabbit antibody that recog-
nizes human (and not mouse) AAT (1:600, Cat#KDI-A1ATRYPabr,
Fitzgerald). Slides were rinsed in 1 TBS, followed by application of
conjugated secondary antibody (Mach 2 goat anti-rabbit horse radish
peroxidase-conjugated, Biocare Medical) for 30 min at RT. Detection
of AAT was achieved by incubating slides in 3030 diaminobenzidine
(Biocare Medical) for 1.5 min at RT. Slides were counterstained
with hematoxylin for 30 s and mounted with Cytoseal XYL
(Richard-Allen Scientific).
PAS-D Staining
Schiff’s reagent was pre-warmed at RT for at least 30 min. Sections
were de-paraffinized and rehydrated. Amylase was applied on the
slides for 20min at RT and rinsed with water. Sections were incubated
in 0.5% Periodic acid for 10 min and rinsed. Schiff’s reagent was
applied to the slides for 15 min. Then sections were washed in luke-
warm tap water for 5 min. Hematoxylin counterstain was applied for
15 s and blue nuclei for 1 min. One slide without amylase treatment
acted as the control.
PSR Staining
PSR staining was performed using the Picrosirius Red Stain Kit
(Cat#24901-250, Polysciences Inc.).
Threshold Analyses
Analyses were carried out blindly by an experienced technician at the
University of Florida Pathology Core.
Model Optimization
Animals were pre-treated with 50 mg/kg MCT (Oakwood Chemical)
intraperitoneally 7 days or 14 and 7 days prior to engraftment or
treated at the time of engraftment with 1 mg purified NA/LE hamster
anti-mouse CD95 antibody (first apoptosis signal [FAS], BD
PharMingen) intravenously.
Flow Cytometry Assay
After dissociation, cells were stained on ice for 30 min with anti-
mouse/human CD324 (Biolegend) and anti-HLA-ABC (BD Biosci-
ences) antibodies to determine human hepatocyte percentage. Cells
were then washed twice with 1 PBS and resuspended in 1 PBS
supplemented with 0.5% FBS and 2 mM EDTA. Cells were acquired
using FACS-LSRII flow cytometer (BD Biosciences) and analyzed
with FlowJo software (version 10.1; Tree Star Inc.).
ddPCR Assay
Genomic DNA was isolated (Gentra Puregene kit, QIAGEN) from
flash-frozen liver and ddPCR (Bio-Rad) was performed according
to the manufacturer’s recommendations using 50 ng of DNA as input
and TaqMan assays detecting GFP and RPP30.
Statistics
Regression analysis was followed by a two-tailed Pearson R test
(Figure 4). Effects of time and treatment were assessed through a
repeated-measure two-way ANOVA (Figure 6C). Statistical signifi-
cance of the difference between age-matched control and treated
groups was determined with a paired t test (Figure 6F). Statistical sig-
nificance was defined as p < 0.05.
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Table S1. Wild-type hepatocytes expand faster than hepatocytes expressing Z-AAT (PiZ). 
 
Genotype 
of host 
mouse 
Genotype 
of 
implanted 
hepatocytes  
Treatment Animal # % GFP (ddPCR) % GFP (IHC) 
NSG-PiZ PiZ-GFP S+PHx 832 9.8 7.7 14 11.3 
848 2.7 12 
849 10.7 7 
S 833 4.5 5.4 16 11.7 
834 8.5 11 
835 3.1 8 
WT-GFP S+PHx 838 42.2 31.9 43 44.5 
840 21.6 46 
S 841 34.7 39.3 50 48.2 
842 39.4 47 
843 45.3 47 
844 37.7 48 
B6-GFP None None NA 94.8 97.5 NA NA 
NA 100.2 NA 
NSG: NOD-scid-gamma, B6: C57BL/6, PiZ: protease inhibitor Z, GFP: green fluorescent protein, 
WT: wild-type, S: splenic injection only, S+PHx: splenic injection and partial hepatectomy, 
ddPCR: droplet digital polymerase chain reaction, IHC: immunohistochemistry, NA: not 
available.  
  
  
Figure S1. Human specificity of anti-HLA antibody. Mouse liver (upper panel) and humanized 
mouse liver engrafted with human hepatocytes (lower panel) were dissociated and stained with 
anti-CD324, anti-CD95 and anti-HLA-ABC antibodies. Hepatocytes were gated as CD324+cells 
and human hepatocytes as CD95-HLA-ABC+ cells within the CD324+ gate. Human hepatocytes 
(CD324+CD95-HLA-ABC+) are detected only in humanized mouse liver confirming the specificity 
of the anti-HLA-ABC antibody for human cells. 
 
